Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
40
ALDX Quote, Financials, Valuation and Earnings
Last price:
$5.09
Seasonality move
:
-2.23%
Day range:
$4.92 - $5.13
52-week range:
$1.14 - $7.20
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
6.21x
Volume:
727.1K
Avg. volume:
774.8K
1-year change:
-25.07%
Market cap:
$305.6M
Revenue:
--
EPS (TTM):
-$0.72
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
ALDX
Aldeyra Therapeutics, Inc.
|
$24.3M | -$0.15 | -- | -45.37% | $9.67 |
|
ALT
Altimmune, Inc.
|
$560 | -$0.24 | -87.6% | -1.45% | $17.67 |
|
ASRT
Assertio Holdings, Inc.
|
$6.2M | -$1.80 | -80.74% | -9.4% | $39.94 |
|
ATNM
Actinium Pharmaceuticals, Inc.
|
-- | -$0.19 | -100% | -59.88% | $5.00 |
|
AVNS
Avanos Medical, Inc.
|
$174.7M | $0.25 | 0.9% | 70.21% | $14.00 |
|
MNOV
MediciNova, Inc.
|
-- | -$0.10 | -100% | -65.51% | $10.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
ALDX
Aldeyra Therapeutics, Inc.
|
$5.08 | $9.67 | $305.6M | -- | $0.00 | 0% | -- |
|
ALT
Altimmune, Inc.
|
$4.49 | $17.67 | $561.7M | -- | $0.00 | 0% | 17,811.29x |
|
ASRT
Assertio Holdings, Inc.
|
$12.06 | $39.94 | $77.4M | -- | $0.00 | 0% | 4.49x |
|
ATNM
Actinium Pharmaceuticals, Inc.
|
$1.11 | $5.00 | $34.6M | -- | $0.00 | 0% | 384.75x |
|
AVNS
Avanos Medical, Inc.
|
$15.21 | $14.00 | $706M | 45.94x | $0.00 | 0% | 1.01x |
|
MNOV
MediciNova, Inc.
|
$1.55 | $10.00 | $76.2M | -- | $0.00 | 0% | 294.77x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
ALDX
Aldeyra Therapeutics, Inc.
|
23.99% | 2.196 | 4.95% | 2.64x |
|
ALT
Altimmune, Inc.
|
7.89% | 0.809 | 4.41% | 16.79x |
|
ASRT
Assertio Holdings, Inc.
|
29.83% | 1.399 | 53.04% | 1.43x |
|
ATNM
Actinium Pharmaceuticals, Inc.
|
7.66% | -2.772 | 2.29% | 7.81x |
|
AVNS
Avanos Medical, Inc.
|
14.67% | 0.636 | 24.92% | 1.26x |
|
MNOV
MediciNova, Inc.
|
0.58% | 0.950 | 0.41% | 9.76x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
ALDX
Aldeyra Therapeutics, Inc.
|
-$63.7K | -$8M | -53.75% | -66.61% | -- | -$7M |
|
ALT
Altimmune, Inc.
|
-$22K | -$20.9M | -53.6% | -56.24% | -417180% | -$11.9M |
|
ASRT
Assertio Holdings, Inc.
|
$30.2M | $12.9M | -18.41% | -25.86% | 26.09% | -$4.8M |
|
ATNM
Actinium Pharmaceuticals, Inc.
|
-$116K | -$5.7M | -126.64% | -133.63% | -6324.44% | -$6.3M |
|
AVNS
Avanos Medical, Inc.
|
$81.1M | $13.1M | -44.75% | -52.63% | 7.37% | $7M |
|
MNOV
MediciNova, Inc.
|
-$39K | -$3.4M | -24.01% | -24.18% | -2742.09% | -$1.7M |
Aldeyra Therapeutics, Inc. vs. Competitors
-
Which has Higher Returns ALDX or ALT?
Altimmune, Inc. has a net margin of -- compared to Aldeyra Therapeutics, Inc.'s net margin of -380280%. Aldeyra Therapeutics, Inc.'s return on equity of -66.61% beat Altimmune, Inc.'s return on equity of -56.24%.
Company Gross Margin Earnings Per Share Invested Capital ALDXAldeyra Therapeutics, Inc.-- -$0.13 $64.8M ALTAltimmune, Inc.-440% -$0.21 $201.5M -
What do Analysts Say About ALDX or ALT?
Aldeyra Therapeutics, Inc. has a consensus price target of $9.67, signalling upside risk potential of 90.29%. On the other hand Altimmune, Inc. has an analysts' consensus of $17.67 which suggests that it could grow by 296.11%. Given that Altimmune, Inc. has higher upside potential than Aldeyra Therapeutics, Inc., analysts believe Altimmune, Inc. is more attractive than Aldeyra Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ALDXAldeyra Therapeutics, Inc.4 0 0 ALTAltimmune, Inc.5 1 1 -
Is ALDX or ALT More Risky?
Aldeyra Therapeutics, Inc. has a beta of 0.984, which suggesting that the stock is 1.635% less volatile than S&P 500. In comparison Altimmune, Inc. has a beta of 0.091, suggesting its less volatile than the S&P 500 by 90.87%.
-
Which is a Better Dividend Stock ALDX or ALT?
Aldeyra Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Altimmune, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Aldeyra Therapeutics, Inc. pays -- of its earnings as a dividend. Altimmune, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ALDX or ALT?
Aldeyra Therapeutics, Inc. quarterly revenues are --, which are smaller than Altimmune, Inc. quarterly revenues of $5K. Aldeyra Therapeutics, Inc.'s net income of -$7.7M is higher than Altimmune, Inc.'s net income of -$19M. Notably, Aldeyra Therapeutics, Inc.'s price-to-earnings ratio is -- while Altimmune, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aldeyra Therapeutics, Inc. is -- versus 17,811.29x for Altimmune, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ALDXAldeyra Therapeutics, Inc.-- -- -- -$7.7M ALTAltimmune, Inc.17,811.29x -- $5K -$19M
-
Which has Higher Returns ALDX or ASRT?
Assertio Holdings, Inc. has a net margin of -- compared to Aldeyra Therapeutics, Inc.'s net margin of 23.14%. Aldeyra Therapeutics, Inc.'s return on equity of -66.61% beat Assertio Holdings, Inc.'s return on equity of -25.86%.
Company Gross Margin Earnings Per Share Invested Capital ALDXAldeyra Therapeutics, Inc.-- -$0.13 $64.8M ASRTAssertio Holdings, Inc.61.01% $1.61 $150.8M -
What do Analysts Say About ALDX or ASRT?
Aldeyra Therapeutics, Inc. has a consensus price target of $9.67, signalling upside risk potential of 90.29%. On the other hand Assertio Holdings, Inc. has an analysts' consensus of $39.94 which suggests that it could grow by 231.16%. Given that Assertio Holdings, Inc. has higher upside potential than Aldeyra Therapeutics, Inc., analysts believe Assertio Holdings, Inc. is more attractive than Aldeyra Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ALDXAldeyra Therapeutics, Inc.4 0 0 ASRTAssertio Holdings, Inc.3 0 0 -
Is ALDX or ASRT More Risky?
Aldeyra Therapeutics, Inc. has a beta of 0.984, which suggesting that the stock is 1.635% less volatile than S&P 500. In comparison Assertio Holdings, Inc. has a beta of 0.775, suggesting its less volatile than the S&P 500 by 22.468%.
-
Which is a Better Dividend Stock ALDX or ASRT?
Aldeyra Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Assertio Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Aldeyra Therapeutics, Inc. pays -- of its earnings as a dividend. Assertio Holdings, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ALDX or ASRT?
Aldeyra Therapeutics, Inc. quarterly revenues are --, which are smaller than Assertio Holdings, Inc. quarterly revenues of $49.5M. Aldeyra Therapeutics, Inc.'s net income of -$7.7M is lower than Assertio Holdings, Inc.'s net income of $11.4M. Notably, Aldeyra Therapeutics, Inc.'s price-to-earnings ratio is -- while Assertio Holdings, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aldeyra Therapeutics, Inc. is -- versus 4.49x for Assertio Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ALDXAldeyra Therapeutics, Inc.-- -- -- -$7.7M ASRTAssertio Holdings, Inc.4.49x -- $49.5M $11.4M
-
Which has Higher Returns ALDX or ATNM?
Actinium Pharmaceuticals, Inc. has a net margin of -- compared to Aldeyra Therapeutics, Inc.'s net margin of -5701.11%. Aldeyra Therapeutics, Inc.'s return on equity of -66.61% beat Actinium Pharmaceuticals, Inc.'s return on equity of -133.63%.
Company Gross Margin Earnings Per Share Invested Capital ALDXAldeyra Therapeutics, Inc.-- -$0.13 $64.8M ATNMActinium Pharmaceuticals, Inc.-128.89% -$0.16 $14.9M -
What do Analysts Say About ALDX or ATNM?
Aldeyra Therapeutics, Inc. has a consensus price target of $9.67, signalling upside risk potential of 90.29%. On the other hand Actinium Pharmaceuticals, Inc. has an analysts' consensus of $5.00 which suggests that it could grow by 350.45%. Given that Actinium Pharmaceuticals, Inc. has higher upside potential than Aldeyra Therapeutics, Inc., analysts believe Actinium Pharmaceuticals, Inc. is more attractive than Aldeyra Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ALDXAldeyra Therapeutics, Inc.4 0 0 ATNMActinium Pharmaceuticals, Inc.3 1 0 -
Is ALDX or ATNM More Risky?
Aldeyra Therapeutics, Inc. has a beta of 0.984, which suggesting that the stock is 1.635% less volatile than S&P 500. In comparison Actinium Pharmaceuticals, Inc. has a beta of -0.303, suggesting its less volatile than the S&P 500 by 130.29%.
-
Which is a Better Dividend Stock ALDX or ATNM?
Aldeyra Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Actinium Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Aldeyra Therapeutics, Inc. pays -- of its earnings as a dividend. Actinium Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ALDX or ATNM?
Aldeyra Therapeutics, Inc. quarterly revenues are --, which are smaller than Actinium Pharmaceuticals, Inc. quarterly revenues of $90K. Aldeyra Therapeutics, Inc.'s net income of -$7.7M is lower than Actinium Pharmaceuticals, Inc.'s net income of -$5.1M. Notably, Aldeyra Therapeutics, Inc.'s price-to-earnings ratio is -- while Actinium Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aldeyra Therapeutics, Inc. is -- versus 384.75x for Actinium Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ALDXAldeyra Therapeutics, Inc.-- -- -- -$7.7M ATNMActinium Pharmaceuticals, Inc.384.75x -- $90K -$5.1M
-
Which has Higher Returns ALDX or AVNS?
Avanos Medical, Inc. has a net margin of -- compared to Aldeyra Therapeutics, Inc.'s net margin of -0.79%. Aldeyra Therapeutics, Inc.'s return on equity of -66.61% beat Avanos Medical, Inc.'s return on equity of -52.63%.
Company Gross Margin Earnings Per Share Invested Capital ALDXAldeyra Therapeutics, Inc.-- -$0.13 $64.8M AVNSAvanos Medical, Inc.45.61% -$0.03 $911.7M -
What do Analysts Say About ALDX or AVNS?
Aldeyra Therapeutics, Inc. has a consensus price target of $9.67, signalling upside risk potential of 90.29%. On the other hand Avanos Medical, Inc. has an analysts' consensus of $14.00 which suggests that it could fall by -7.96%. Given that Aldeyra Therapeutics, Inc. has higher upside potential than Avanos Medical, Inc., analysts believe Aldeyra Therapeutics, Inc. is more attractive than Avanos Medical, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ALDXAldeyra Therapeutics, Inc.4 0 0 AVNSAvanos Medical, Inc.0 1 0 -
Is ALDX or AVNS More Risky?
Aldeyra Therapeutics, Inc. has a beta of 0.984, which suggesting that the stock is 1.635% less volatile than S&P 500. In comparison Avanos Medical, Inc. has a beta of 1.089, suggesting its more volatile than the S&P 500 by 8.883%.
-
Which is a Better Dividend Stock ALDX or AVNS?
Aldeyra Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Avanos Medical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Aldeyra Therapeutics, Inc. pays -- of its earnings as a dividend. Avanos Medical, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ALDX or AVNS?
Aldeyra Therapeutics, Inc. quarterly revenues are --, which are smaller than Avanos Medical, Inc. quarterly revenues of $177.8M. Aldeyra Therapeutics, Inc.'s net income of -$7.7M is lower than Avanos Medical, Inc.'s net income of -$1.4M. Notably, Aldeyra Therapeutics, Inc.'s price-to-earnings ratio is -- while Avanos Medical, Inc.'s PE ratio is 45.94x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aldeyra Therapeutics, Inc. is -- versus 1.01x for Avanos Medical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ALDXAldeyra Therapeutics, Inc.-- -- -- -$7.7M AVNSAvanos Medical, Inc.1.01x 45.94x $177.8M -$1.4M
-
Which has Higher Returns ALDX or MNOV?
MediciNova, Inc. has a net margin of -- compared to Aldeyra Therapeutics, Inc.'s net margin of -2473.97%. Aldeyra Therapeutics, Inc.'s return on equity of -66.61% beat MediciNova, Inc.'s return on equity of -24.18%.
Company Gross Margin Earnings Per Share Invested Capital ALDXAldeyra Therapeutics, Inc.-- -$0.13 $64.8M MNOVMediciNova, Inc.-31.63% -$0.06 $44.2M -
What do Analysts Say About ALDX or MNOV?
Aldeyra Therapeutics, Inc. has a consensus price target of $9.67, signalling upside risk potential of 90.29%. On the other hand MediciNova, Inc. has an analysts' consensus of $10.00 which suggests that it could grow by 545.16%. Given that MediciNova, Inc. has higher upside potential than Aldeyra Therapeutics, Inc., analysts believe MediciNova, Inc. is more attractive than Aldeyra Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ALDXAldeyra Therapeutics, Inc.4 0 0 MNOVMediciNova, Inc.2 0 0 -
Is ALDX or MNOV More Risky?
Aldeyra Therapeutics, Inc. has a beta of 0.984, which suggesting that the stock is 1.635% less volatile than S&P 500. In comparison MediciNova, Inc. has a beta of 0.548, suggesting its less volatile than the S&P 500 by 45.242%.
-
Which is a Better Dividend Stock ALDX or MNOV?
Aldeyra Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. MediciNova, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Aldeyra Therapeutics, Inc. pays -- of its earnings as a dividend. MediciNova, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ALDX or MNOV?
Aldeyra Therapeutics, Inc. quarterly revenues are --, which are smaller than MediciNova, Inc. quarterly revenues of $123.3K. Aldeyra Therapeutics, Inc.'s net income of -$7.7M is lower than MediciNova, Inc.'s net income of -$3.1M. Notably, Aldeyra Therapeutics, Inc.'s price-to-earnings ratio is -- while MediciNova, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aldeyra Therapeutics, Inc. is -- versus 294.77x for MediciNova, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ALDXAldeyra Therapeutics, Inc.-- -- -- -$7.7M MNOVMediciNova, Inc.294.77x -- $123.3K -$3.1M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Sell
49
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 35x
Sell
44
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Sell
23
CAR alert for Feb 20
Avis Budget Group, Inc. [CAR] is down 21.87% over the past day.
Buy
75
HYMC alert for Feb 20
Hycroft Mining Holding Corp. [HYMC] is up 3.81% over the past day.
Sell
1
EPAM alert for Feb 20
EPAM Systems, Inc. [EPAM] is down 16.79% over the past day.
